Biopharma Transcript

ClearPoint Neuro, Inc. CLPT

Nasdaq · CNS/neurology/psychiatry · device-combination · EDGAR · Updated Nov 4, 2026

ClearPoint Neuro, Inc. (Nasdaq: CLPT) is a CNS/neurology/psychiatry medical device company.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Pipeline

ProgramIndicationModalityStage
ClearPoint system (MRI-guided neurosurgery)General neurosurgical proceduresdevice-combinationNA_NON_THERAPEUTIC
SmartFrame OR Stereotactic SystemOperating room neurosurgerydevice-combinationNA_NON_THERAPEUTIC
ClearPoint Prism Neuro Laser Therapy SystemLaser ablation neurosurgerydevice-combinationNA_NON_THERAPEUTIC
IRRAflow systemIntracerebral hemorrhage, intraventricular hemorrhage, neurocritical caredevice-combinationNA_NON_THERAPEUTIC
SmartFlow cannulaGene therapy delivery for aromatic L-amino acid decarboxylase deficiencydevice-combinationNA_NON_THERAPEUTIC

Recent results and decisions

  1. Oct 28, 2026
    submitted First formal BLA was submitted by one partner for the treatment of Huntington's Disease.First formal BLA was submitted by one partner for the treatment of Huntington's Disease; Filing
  2. Oct 28, 2026
    submitted First formal BLA was submitted by one partner for the treatment of Huntington's Disease.First formal BLA was submitted by one partner for the treatment of Huntington's Disease Filing
  3. Oct 28, 2026
    submitted First formal BLA submitted by one partner for the treatment of Huntington's Disease.First formal BLA was submitted by one partner for the treatment of Huntington's Disease Filing

2 more on record.

For subscribers

See plansOpen in the tracker

Other CNS/neurology/psychiatry companies